Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of amivantamab + lazertinib + platinum chemotherapy versus platinum chemotherapy after osimertinib failure in EGFR-mutant advanced non-small cell lung cancer
CTR20212717Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amivantamab, lazertinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Jan 2022; status: active.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212717.